Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis-Reference-Cited by-同舟云学术

Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wang Ya-Kun¹,Wu Yue-E²,Li Xue²,Tian Li-Yuan¹,Khan Muhammad Wasim²,Tang Bo-Hao²,Shi Hai-Yan³,Zheng Yi²,Hao Guo-Xiang²,van den Anker John⁴⁵⁶⁷⁸,You Dian-Ping⁹,Zhao Wei²³⁹^ORCID

Affiliation:

1. Department of Respiratory Care, Children's Hospital of Hebei Province, Shijiazhuang, China

2. Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

3. Department of Clinical Pharmacy, Clinical Trial Center, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China

4. Division of Clinical Pharmacology, Children’s National Medical Center, Washington, DC, USA

5. Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

6. Department of Pharmacology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

7. Department of Physiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

8. Department of Paediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel, Basel, Switzerland

9. Pediatric Research Institute, Children's Hospital of Hebei Province, Shijiazhuang, China

Abstract

Ceftriaxone is a third-generation cephalosporin used to treat infants with community-acquired pneumonia. Currently, there is a large variability in the amount of ceftriaxone used for this purpose in this particular age group, and an evidence-based optimal dose is still unavailable. Therefore, we investigated the population pharmacokinetics of ceftriaxone in infants and performed a developmental pharmacokinetic-pharmacodynamic analysis to determine the optimal dose of ceftriaxone for the treatment of infants with community-acquired pneumonia.

Funder

National Science and Technology Major Projects for “Major New Drugs Innovation and Development”

Scientific Research Foundation for the High-Level Returned Overseas Chinese Scholars

Hundred-Talent Program

Young Taishan Scholars Program of Shandong Province

Qilu Young Scholars Program of Shandong University

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01412-20